^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD47 inhibitor

    Related drugs:
    2d
    HX009-II-02: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1/2, N=48, Completed, Hangzhou Hanx Biopharmaceuticals, Ltd. | Recruiting --> Completed | N=99 --> 48 | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Dec 2025 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HX-009
    5d
    A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) (clinicaltrials.gov)
    P1, N=9, Terminated, Aurigene Discovery Technologies Limited | N=42 --> 9 | Trial completion date: Jan 2027 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Feb 2026; Patient recruitment problems
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    AU7R-104 • XL114
    7d
    Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=20, Completed, Hangzhou Hanx Biopharmaceuticals, Ltd. | Active, not recruiting --> Completed | N=210 --> 20
    Trial completion • Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    HX-009
    7d
    A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. (clinicaltrials.gov)
    P1, N=18, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase classification: P2 --> P1
    Phase classification
    |
    CRP (C-reactive protein)
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    9d
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=59, Active, not recruiting, Pfizer | Trial primary completion date: Apr 2026 --> Jul 2025
    Trial primary completion date
    |
    carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    9d
    A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome. (clinicaltrials.gov)
    P2, N=18, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | N=30 --> 18 | Trial completion date: Jun 2026 --> Oct 2026 | Trial primary completion date: Jun 2026 --> Oct 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    danburstotug (IMC-001) • timdarpacept (IMM01)
    13d
    Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma (clinicaltrials.gov)
    P1, N=7, Terminated, Conjupro Biotherapeutics, Inc. | Phase classification: P1/2 --> P1
    Phase classification • First-in-human
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CD20 positive
    |
    JMT601
    15d
    ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, ALX Oncology Inc. | Phase classification: P1/2 --> P2 | N=80 --> 120 | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Jun 2027 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • gemcitabine • paclitaxel • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • evorpacept (ALX148)
    16d
    Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=58, Terminated, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Terminated; Adjusted the product development strategy.
    Trial termination
    20d
    ILLUMINE: Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (clinicaltrials.gov)
    P3, N=780, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab) • ligufalimab (AK117)
    26d
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=59, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=90 --> 59
    Enrollment closed • Enrollment change
    |
    carfilzomib • dexamethasone • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    27d
    RRx-001 inhibits G6PD to deplete NADPH and trigger disulfidptosis coupled with DAMP-mediated immunogenic cell death in hepatocellular carcinoma. (PubMed, Cell Death Discov)
    In vivo, RRx-001 significantly inhibits tumor growth, enhances T-cell infiltration, promotes M1 macrophage polarization, downregulates PD-L1 expression, and strengthens anti-tumor immunity through T cell-related pathways. With both metabolic and immunomodulatory effects, RRx-001 provides a basis for novel HCC therapies, and future research could explore its synergistic effects with immune checkpoint inhibitors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • HMGB1 (High Mobility Group Box 1) • G6PD (Glucose-6-Phosphate Dehydrogenase)
    |
    PD-L1 expression
    |
    nibrozetone (RRx-001)